Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Growth hormone & endocrine research

CJC-1295 with DAC (CJC-1295 DAC): Research Overview

Long-acting version of the same GHRH analogue, modified to stay in circulation for days.

Also known as CJC-1295 with DAC · drug affinity complex GHRH · CJC-1295 DAC

Research use onlyStrongest evidence: early human studyReviewed
DatabaseReferences

What is CJC-1295 with DAC?

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

What is CJC-1295 with DAC researched for?

  • Continuous growth hormone release for 6-8 days per injection.
  • Significantly elevates IGF-1 levels for extended periods.
  • Weekly dosing ideal for simple administration.
  • Continuous GH elevation promotes lipolysis and fat metabolism.
  • Sustained anabolic environment supports muscle protein synthesis.
  • Accelerated healing and recovery from exercise or injury.

How does CJC-1295 with DAC work?

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

Reported targets: GHRH receptor

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL, Neale A, Lawrence B, et al. · The Journal of clinical endocrinology and metabolism · 2006

    Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.

    Early human study · PMID 16352683

  2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

    Ionescu M, Frohman LA · The Journal of clinical endocrinology and metabolism · 2006

    Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.

    PMID 17018654

  3. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

    Jetté L, Léger R, Thibaudeau K, et al. · Endocrinology · 2005

    Identified CJC-1295 as a long-acting GHRH analog through albumin bioconjugation (DAC technology). Binds covalently to endogenous albumin, extending half-life from minutes to days.

    Animal study · PMID 15817669

  4. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

    Sackmann-Sala L, Ding J, Frohman LA, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009

    Long-acting GHRH stimulation via CJC-1295 produces measurable changes in serum protein profiles reflecting sustained GH/IGF-1 axis activation.

    PMID 19386527

  5. This information is for educational and research purposes only. Consult a healthcare professional before use.

  6. A comprehensive research database for peptides, therapies, and protocols. Information provided for educational purposes only.

  7. © 2026 Peptide Database. For educational and research purposes only.

Common questions

Why does some people report joint pain during CJC-1295 DAC use?

Joint pain and carpal tunnel symptoms occur due to sustained GH and IGF-1 elevation causing water retention in joints and connective tissues. Unlike pulsatile protocols where GH spikes then drops, the 6-8 day DAC half-life creates continuous elevation that may stress joints, particularly in high-dose users.